Spots Global Cancer Trial Database for LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
Official Title: A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors
Study ID: NCT00556088
Conditions
Interventions
Study Description
Brief Summary: This phase I protocol will evaluate the safety and tolerability of the combination of LBH589 and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a subset of patients with advanced non-small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Contact Details
Name: Howard A. Burris, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
